-transparent.png){kind=logo}
Immunohistological detection of P-glycoprotein (P-gp) with monoclonal antibody C219 was performed on serial sections of 37 neuroblastoma specimens representative of the different forms of the disease, from stage 1 ganglioneuroma to stage 4 neuroblastoma. Malignant cells, irrespective of their degree of maturation varying from neuroblasts to ganglion cells, were negative on all specimens. The expression of P-glycoprotein was detected in nine specimens, but it was restricted to normal cells within the tumour. In four specimens, C219 reacted with normal infiltrating cells in the stroma (i.e. monocytes, histiocytes or fibroblasts) representing 5 to 10% of the total population within the section; in three specimens, the residual adrenal gland was strongly positive, and in two ganglioneuromas, a weak reactivity of C219 was observed on a few satellite cells and schwann cells. Three of 15 biopsies obtained at diagnosis contained normal P-gp positive cells: two were classified as stage 1 ganglioneuromas; one was a typical stage 4 composite tumours with positive histiocytes and fibroblasts in the well-differentiated counterpart. Six of 22 biopsies obtained after patients had received our current protocol of chemotherapy contained normal P-gp positive cells: five were partially differentiated and necrotic under the effect of chemotherapy; only one positive specimen was classified as undifferentiated neuroblastoma. Among negative specimens from previously treated patients, one was obtained from a patient in relapse after high-dose chemotherapy and ABMT, two were obtained from patients who had not responded to induction therapy, and six from patients in partial remission after induction therapy. The clinical evolution was very similar in both groups of patients with P-gp negative or positive biopsies. These findings suggest that the quantitative assessment of MDR RNA by northern blotting on fresh homogenates is likely to overestimate its expression on neuroblastoma cells, and that the mechanism of chemoresistance in widespread neuroblastoma is less likely to be associated with P-gp expression.
M Favrot, and
V Combaret, and
E Goillot, and
J P Wagner, and
E Bouffet, and
F Mazingue, and
A Thyss, and
P Bordigoni, and
G Delsol, and
C Bailly
April 1992,
The New England journal of medicine,
M Favrot, and
V Combaret, and
E Goillot, and
J P Wagner, and
E Bouffet, and
F Mazingue, and
A Thyss, and
P Bordigoni, and
G Delsol, and
C Bailly
January 1995,
The Journal of pathology,
M Favrot, and
V Combaret, and
E Goillot, and
J P Wagner, and
E Bouffet, and
F Mazingue, and
A Thyss, and
P Bordigoni, and
G Delsol, and
C Bailly
August 1991,
The American journal of pathology,
M Favrot, and
V Combaret, and
E Goillot, and
J P Wagner, and
E Bouffet, and
F Mazingue, and
A Thyss, and
P Bordigoni, and
G Delsol, and
C Bailly
September 1998,
Annals of oncology : official journal of the European Society for Medical Oncology,
M Favrot, and
V Combaret, and
E Goillot, and
J P Wagner, and
E Bouffet, and
F Mazingue, and
A Thyss, and
P Bordigoni, and
G Delsol, and
C Bailly
January 1994,
Cold Spring Harbor symposia on quantitative biology,
M Favrot, and
V Combaret, and
E Goillot, and
J P Wagner, and
E Bouffet, and
F Mazingue, and
A Thyss, and
P Bordigoni, and
G Delsol, and
C Bailly
October 1992,
Archives of pathology & laboratory medicine,
M Favrot, and
V Combaret, and
E Goillot, and
J P Wagner, and
E Bouffet, and
F Mazingue, and
A Thyss, and
P Bordigoni, and
G Delsol, and
C Bailly
May 2011,
Experimental dermatology,
M Favrot, and
V Combaret, and
E Goillot, and
J P Wagner, and
E Bouffet, and
F Mazingue, and
A Thyss, and
P Bordigoni, and
G Delsol, and
C Bailly
October 1997,
Cancer,
M Favrot, and
V Combaret, and
E Goillot, and
J P Wagner, and
E Bouffet, and
F Mazingue, and
A Thyss, and
P Bordigoni, and
G Delsol, and
C Bailly
May 1994,
Blood,
M Favrot, and
V Combaret, and
E Goillot, and
J P Wagner, and
E Bouffet, and
F Mazingue, and
A Thyss, and
P Bordigoni, and
G Delsol, and
C Bailly
March 1997,
Journal of pediatric surgery,
